What Diafer Treats: Main Uses and Benefits

Diafer is primarily used for managing Iron Deficiency Anemia (IDA) in adult patients who have experienced intolerance to oral iron supplements or have had an unsatisfactory response to them. This therapy may assist with addressing the deficiency and is relevant in contexts marked by systemic imbalance or inflammatory states.

The medication is commonly used to help with conditions like anemia associated with Chronic Kidney Disease (NDD-CKD), anemia linked to Gastrointestinal Malabsorption, and deficiency caused by Inflammatory Bowel Disease. This approach helps alleviate symptom clusters that interfere with daily functioning, such as profound chronic fatigue, weakness, and general physical discomfort.

“This supportive therapy is applied in clinical settings that involve chronic conditions where functional stability becomes affected.”

By supporting the body's iron supply, Diafer contributes to raising Hemoglobin levels and assists with maintaining functional stability, offering supportive relief when symptoms interfere with routine activities.

---

Quick Fact: Support for Chronic Fatigue

Diafer is considered relevant for easing the symptom burden of IDA, including chronic fatigue and lethargy, which are symptoms related to systemic imbalance and create noticeable physiological strain.

Eligibility Scope and Restrictions

Diafer (Ferric Derisomaltose) is authorized for use in adults who have iron deficiency anemia and who cannot take or have not responded well to oral iron treatments. In some regions, its established use includes adults with chronic kidney disease (CKD).

Category	Regulatory Status
Populations Contraindicated	Patients with known serious hypersensitivity to the drug or its components. Patients with evidence of iron overload (e.g., hemochromatosis) or problems with iron utilization.
Use Not Recommended	Children and adolescents under 18 years of age due to insufficient data on safety and efficacy in the pediatric population.

Conditional Use applies to certain groups, including those with a history of severe allergies, immune conditions (like rheumatoid arthritis), or severe asthma, due to an increased risk of hypersensitivity reactions. The medicine must only be administered in a setting where staff and equipment are immediately available to manage severe allergic reactions.

Pregnancy and Lactation: Use during pregnancy requires careful assessment, with regulatory guidance advising avoidance during the first trimester. For lactating women, the medicine is generally considered safe, as only small amounts of the iron are transferred to breast milk.

Interactions with other medicines and products

The official regulatory documentation for Diafer (ferric derisomaltose) specifies interaction patterns that primarily relate to its function as a parenteral iron replacement product and its method of administration. These documented interactions do not involve classic metabolic or transporter pathways, such as the cytochrome P450 enzyme system, which are not listed in the product's regulatory profile.

The most clinically relevant interaction is a pharmacokinetic one involving co-administered Oral Iron Preparations. The systemic presence of intravenous iron has been shown to decrease the absorption of oral iron products when they are administered simultaneously or closely together. This requires a mandatory timing rule: the administration of oral iron must be delayed until at least 5 days after the last injection of ferric derisomaltose.

Interaction-Related Restrictions

The official labeling outlines a key procedural constraint based on physical and chemical incompatibility. Ferric derisomaltose should not be mixed with or physically added to solutions containing other drugs due to established compatibility limitations. Regulatory sources do not document specific interactions with food, alcohol, or herbal products.

Ferric derisomaltose is engineered for controlled release, delivering ferric iron ( Fe^3+) directly to the Reticuloendothelial System (RES) macrophages following intravenous administration. Inside these cells, the iron is liberated at a controlled, gradual rate through the enzymatic degradation of the carbohydrate shell, thereby bypassing the regulatory controls inherent to gastrointestinal absorption.

The released iron immediately binds to the plasma transport protein transferrin. This transferrin-bound iron is specifically targeted to the Transferrin Receptor (TfR1) on erythroid precursor cells in the bone marrow. This targeted delivery supplies the non-negotiable substrate required for the final step of heme synthesis and subsequent hemoglobin production, directly supporting the erythropoiesis pathway.

Beyond hematopoiesis, the delivered iron replenishes intracellular ferritin stores and restores function to iron-dependent metalloenzymes, particularly those within the Mitochondrial Electron Transport Chain. The reversal of this cellular energy deficit is the resultant physiological consequence, leading to the restoration of tissue oxygenation and cellular function.

Administration Guidelines for Diafer

Diafer is administered exclusively by the intravenous (IV) route through either a bolus injection or directly into the venous limb of the dialyser during a haemodialysis session. It may be administered undiluted or diluted in up to 20 mL of sterile 0.9% sodium chloride; no other solutions or agents are permitted for mixture, and the diluted solution must be visually inspected to be clear and free of sediment.

Official Dosing and Frequency

For adults and the elderly, the maximum single dose administered at any one time is 200 mg of elemental iron. The maximum allowable cumulative dose per week is 1000 mg of iron. The total required iron dose must be individualised by a healthcare professional based on the patient's current iron status, including assessment of haemoglobin and ferritin levels. Use in children and adolescents under 18 years is not recommended due to insufficient data.

Procedural and Safety Requirements

Administration must only take place in a setting where staff trained in the evaluation and management of anaphylactic reactions are immediately available, and where full resuscitation facilities are assured.

Procedural Steps:

• Determine the individual dose, not exceeding the maximum single-time limit.
• Administer the prepared solution intravenously, avoiding extravasation (paravenous leakage), which must result in immediate cessation of the injection if it occurs.
• The patient must be observed for adverse effects for at least 30 minutes following the completion of each injection.
• Oral iron preparations should not be started earlier than five days following the last injection of Diafer.

Research Evidence / Overview of Studies for Diafer

Evidence for Use in Iron Deficiency Anemia (IDA)

The research for Diafer (ferric derisomaltose) has been conducted primarily in adult patients with Iron Deficiency Anemia (IDA) who met criteria for intolerance or inadequate response to oral iron supplements. These investigations used large, multi-center Randomized Controlled Trials (RCTs). The research objectives focused on changes in iron biomarkers following Diafer administration in patients with deficiency potentially related to conditions such as chronic blood loss or malabsorption.

The primary focus of these short-term studies was to monitor key blood markers related to iron status. Researchers studied changes in Hemoglobin (Hb) levels and measured the increase in Serum Ferritin (SF) and Transferrin Saturation (TSAT). Studies reported measurements of increases in these hematological markers in observed participants at pre-defined assessment times, typically within a few weeks of administration. Research describes the findings for the primary hematological endpoints reported across the major RCTs that used an active IV iron comparator.

Evidence for Use in Iron Deficiency Anemia with Chronic Kidney Disease (CKD)

Diafer was evaluated in adults with Iron Deficiency Anemia (IDA) linked to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD). The research included dedicated Randomized Controlled Trials (RCTs) that were designed to evaluate Diafer in comparison with other IV iron preparations. Research examined temporary physiological imbalance in this specific population, associated with iron deficiency. The studies primarily monitored the participants' blood markers, looking for changes in Hb, SF, and TSAT over defined time intervals. Findings describe the patterns observed in the studies, including the measured increases in these hematological markers in the participant groups.

What is Still Uncertain and Areas for Future Research

What remains uncertain is the full extent of the long-term changes in patient experience. The primary follow-up for the main findings was typically short-term (4 to 8 weeks), and there is limited information for long-term outcomes regarding the sustained changes in symptoms like chronic fatigue and quality of life across the general IDA population. The research provides context but not individual predictions about the maintenance of iron stores or patterns related to re-treatment over many years.

Common questions about Diafer (FAQ)

Q: What is Diafer?

A: Diafer is a prescription medication used to treat Type 2 diabetes mellitus in adults. It belongs to a class of drugs called SGLT2 inhibitors (sodium-glucose cotransporter 2 inhibitors). Diafer works by helping the kidneys remove glucose (sugar) from the bloodstream through the urine, which helps to lower blood sugar levels.

Q: How should I take Diafer?

A: Diafer is typically taken once daily in the morning, with or without food. You should swallow the tablet whole with a glass of water. It's important to take Diafer exactly as prescribed by your healthcare provider. Do not stop taking it without consulting your doctor.

Q: What are the common side effects of Diafer?

A: The most common side effects of Diafer can include:

• Yeast infections in the genital area (vaginal or penile)
• Urinary tract infections (UTIs)
• Increased urination or need to urinate more often
• Thirst
• Nausea

Contact your healthcare provider if you experience side effects that are severe or do not go away.

Q: Can I drink alcohol while taking Diafer?

A: You should limit the amount of alcohol you drink while taking Diafer, or avoid it entirely, as instructed by your doctor. Alcohol can affect your blood sugar levels and may increase the risk of certain side effects, such as a rare but serious condition called ketoacidosis.

Q: What should I do if I miss a dose of Diafer?

A: If you miss a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time to make up for a missed dose. If you are unsure, consult your healthcare provider or pharmacist.

Q: Can Diafer be used for Type 1 diabetes?

A: No, Diafer is not approved for treating Type 1 diabetes or for treating diabetic ketoacidosis (DKA). It is specifically indicated for the treatment of Type 2 diabetes in adults.

How to Store and Dispose of Diafer (Ferric Derisomaltose)

The official storage and disposal requirements for Diafer (ferric derisomaltose injection) are designed for a prescription, single-use, parenteral medication administered in a clinical setting.

---

Storage and Stability

Condition	Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C).
Prohibited	Do not freeze the vials.
Handling	Vials must be visually inspected for clarity; do not mix with other products except 0.9% sodium chloride.
Stability (Diluted)	The diluted solution is chemically stable for 8 hours at room temperature when the concentration is not less than 1 mg iron/mL.

---

Disposal Requirements

Diafer is for single use only. Any unused solution or waste material must be disposed of in accordance with local requirements. The labeling mandates that the product must not be allowed to enter drains or the environment. Storage and handling are managed by healthcare professionals.